There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Neos Therapeutics (NASDAQ:NEOS), Rocket Pharmaceuticals Inc (NASDAQ:RCKT) and Syndax Pharmaceuticals Inc (NASDAQ:SNDX) with bullish sentiments.
Neos Therapeutics (NEOS)
In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Neos Therapeutics, with a price target of $20. The company’s shares opened today at $6, close to its 52-week low of $5.30.
Chen wrote:
“. Post a solid quarter of execution in 2Q18, we reiterate our OW rating and 12-month PT of $20. The peak sales potential of NEOS’s ADHD platform and pipeline are underappreciated, in our view. We think continued success with the sales of its key drugs (Adzenys Adzenys ER) as well as pipeline advancements will drive upwards earnings revisions to levels not reflected in the consensus and move NEOS’s stock higher. NEOS shares are trading +4% intraday.”
According to TipRanks.com, Chen ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -5.0% and a 41.8% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Melinta Therapeutics Inc, and Aclaris Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Neos Therapeutics with a $15 average price target.
See today’s analyst top recommended stocks >>
Rocket Pharmaceuticals Inc (RCKT)
In a report released today, Phil Nadeau from Cowen & Co. maintained a Buy rating on Rocket Pharmaceuticals Inc. The company’s shares opened today at $21.24, close to its 52-week high of $24.28.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 13.2% and a 55.7% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals Inc, Voyager Therapeutics Inc, and Alexion Pharmaceuticals.
The the analyst consensus on Rocket Pharmaceuticals Inc is currently a Moderate Buy rating.
Syndax Pharmaceuticals Inc (SNDX)
H.C. Wainwright analyst Edward White maintained a Buy rating on Syndax Pharmaceuticals Inc today and set a price target of $30. The company’s shares opened today at $6.75, close to its 52-week low of $6.10.
White observed:
“Valuation: We base our $30 price target on probability-adjusted revenue forecasts for entinostat in combination with other drugs in advanced HR+, HER2- breast cancer, NSCLC, and metastatic melanoma. We use the net present value of our revenue forecast through 2027, apply a 35% POS for HR+, HER2- breast cancer, and 10% POS for NSCLC and melanoma, with a 3x price/sales multiple, and we value the early stage pipeline at $10 million, the amount of the upfront payments the company made to acquire the menin inhibitors and SNDX-6352, to arrive at our price target.”
According to TipRanks.com, White is a 5-star analyst with an average return of 26.1% and a 55.7% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Synthetic Biologics Inc, and Karyopharm Therapeutics.
Syndax Pharmaceuticals Inc has an analyst consensus of Strong Buy, with a price target consensus of $30.67.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
